ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,049 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 951-975 of 1,000 matching filings.

Per page
25
Current page
39
6-K File 001-11960

HOLDING(S) IN COMPANY

Filing date
04 Oct 2019
Reporting date
04 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATION

Filing date
04 Oct 2019
Reporting date
04 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR DECLARATION

Filing date
03 Oct 2019
Reporting date
03 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
3 File 001-39067

FORM 3 SUBMISSION

Filing date
02 Oct 2019
Reporting date
02 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Oct 2019
Reporting date
01 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR

Filing date
01 Oct 2019
Reporting date
01 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD

Filing date
01 Oct 2019
Reporting date
01 Oct 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN

Filing date
30 Sep 2019
Reporting date
30 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS

Filing date
30 Sep 2019
Reporting date
30 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN

Filing date
30 Sep 2019
Reporting date
30 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP

Filing date
23 Sep 2019
Reporting date
23 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-11960

25-NSE filing

Filing date
18 Sep 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA

Filing date
18 Sep 2019
Reporting date
18 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP

Filing date
09 Sep 2019
Reporting date
09 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE

Filing date
04 Sep 2019
Reporting date
04 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Sep 2019
Reporting date
03 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC

Filing date
03 Sep 2019
Reporting date
03 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART

Filing date
03 Sep 2019
Reporting date
03 Sep 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS

Filing date
29 Aug 2019
Reporting date
29 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS

Filing date
28 Aug 2019
Reporting date
28 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS

Filing date
28 Aug 2019
Reporting date
28 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND

Filing date
22 Aug 2019
Reporting date
22 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW

Filing date
22 Aug 2019
Reporting date
22 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON THE PHASE III NEPTUNE TRIAL

Filing date
21 Aug 2019
Reporting date
21 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE III

Filing date
20 Aug 2019
Reporting date
20 Aug 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .